Redx Pharma plc Re: Porcupine inhibitor and cancer immunotherapy (1362K)
September 19 2016 - 2:01AM
UK Regulatory
TIDMREDX
RNS Number : 1362K
Redx Pharma plc
19 September 2016
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company")
Redx confirms potential role for Porcupine inhibitor in cancer
immunotherapy
Redx, the drug development company, is pleased to confirm that
its lead cancer treatment, the Porcupine inhibitor (RXC004), has a
potential role in cancer immunotherapy. Redx scientists have
demonstrated that the Porcupine inhibitor could have a crucial role
in improving the immune system response of some cancer patients
when used in combination with an existing immunotherapy,
anti-programmed cell death-1 (anti-PD-1).
Anti-PD-1 therapy activates the immune system to recognise and
attack tumours. While treatment with PD-1 inhibitors, also known as
Checkpoint inhibitors, is a significant breakthrough in cancer
treatment, not all patients respond.
Redx has been testing a combination therapy that uses both the
Porcupine inhibitor RXC004 and an anti-PD-1 antibody in a cancer
model. The data demonstrates that the combination therapy
significantly improves the ratio of favourable T-cells, which
attack tumours, to the immunosuppressive T-cells that allow tumours
to grow unrecognised, when compared to only using an anti-PD-1
therapy. This suggests that a combination therapy could potentially
improve patient response rates.
Redx's novel, potent small molecule Porcupine inhibitor has
already shown, in disease models, that it has potential as a
stand-alone therapy for difficult to treat cancers, such as
pancreatic cancer.
As previously reported, first-in-human studies for the Porcupine
inhibitor, initially as a stand-alone therapy, are expected to
commence early in 2017. In addition, Redx is now evaluating
opportunities for combination therapies.
Neil Murray, CEO of Redx, commented:
"The results so far from our Porcupine inhibitor, RXC004, have
been very impressive, with important implications for difficult to
treat cancers, such as pancreatic cancer.
Over the past few years, significant progress has been made in
harnessing the ability of the immune system to attack cancer. We
are very pleased that our new findings confirm that our lead cancer
treatment, the Porcupine inhibitor RXC004, now also has a
potentially crucial role in enhancing existing cancer immunotherapy
treatments.
Our Porcupine program has progressed from concept to moving
towards first-in-human clinical trials in a little under three
years, which is a remarkable achievement and evidence of our
commercially disciplined approach and outstanding scientific
capabilities."
For further information, please contact:
Redx Pharma Plc
Neil Murray, Chief Executive T: +44 151
706 4747
Karl Hård, Head of Investor T: +44 7491
Relations & 651 406
Corporate Communications
Company website: redxpharma.com
Cantor Fitzgerald Europe (Nomad T: +44 020
& Broker) 7894 7000
Phil Davies / Michael Reynolds
T: +44 020
KTZ Communications 3178 6378
Katie Tzouliadis/ Viktoria Langley/
Emma Pearson
About Redx Pharma Plc
www.redxpharma.com
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a portfolio of 14 proprietary drug programs. Seven
proof of concepts have been achieved across five programs, with
relevance for respective therapies to treat MRSA, gonorrhea, bone
tumours, skin, brain, breast, pancreatic and blood cancers.
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFMEFAFMSESU
(END) Dow Jones Newswires
September 19, 2016 02:01 ET (06:01 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024